Physician profile
Anan Said
NPI 1780983205
$34,959.03
in general payments reported to CMS, 2019-2025
32 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $355 · 2021: $1,025 · 2022: $1,025 · 2023: $750 · 2024: $15K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $4,764 · Travel and Lodging: $446 · Education: $15.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,750.00 |
| Food and Beverage | $4,764.29 |
| Travel and Lodging | $446.09 |
| Education | $15.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28,135.95 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,778.23 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $917.26 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $758.70 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $720.17 | 2021-2025 | Tremfya, Stelara, Simponi |
| Actuated Medical, INC. | $700.00 | 2021-2022 | |
| Ardelyx, INC. | $195.19 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $167.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $164.38 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $162.99 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $138.98 | 2023-2024 | Omvoh |
| Pfizer INC. | $124.20 | 2019-2024 | |
| Celgene Corporation | $108.82 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $84.28 | 2022-2024 | |
| Daiichi Sankyo INC. | $81.26 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $80.88 | 2020-2025 | Rebyota |
| Braintree Laboratories, INC. | $75.18 | 2021-2022 | |
| Celltrion USA INC. | $67.89 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $66.94 | 2020-2025 | |
| Biofire Diagnostics, LLC | $59.68 | 2020 | |
| Merck Sharp & Dohme LLC | $58.77 | 2019-2024 | Dificid |
| Allergan, INC. | $50.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $45.54 | 2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $39.76 | 2022-2023 | Linzess |
| Qol Medical, LLC | $38.10 | 2022 | |
| Meridian Bioscience INC. | $24.76 | 2023 | |
| Shire North American Group INC | $24.58 | 2019 | |
| Amgen INC. | $24.19 | 2020-2021 | |
| Dova Pharmaceuticals | $20.06 | 2019 | |
| Neurocrine Biosciences, INC. | $18.52 | 2024 | Ingrezza |
| Olympus America INC. | $13.53 | 2019 | |
| Aries Pharmaceuticals, INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anan Said listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.